Brokerages Anticipate Charles River Laboratories Intl. Inc (NYSE:CRL) to Announce $1.57 Earnings Per Share

Share on StockTwits

Equities analysts predict that Charles River Laboratories Intl. Inc (NYSE:CRL) will report earnings of $1.57 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Charles River Laboratories Intl.’s earnings, with the lowest EPS estimate coming in at $1.52 and the highest estimate coming in at $1.61. Charles River Laboratories Intl. reported earnings per share of $1.62 during the same quarter last year, which suggests a negative year over year growth rate of 3.1%. The firm is expected to announce its next earnings results on Wednesday, August 14th.

On average, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $6.48 per share for the current fiscal year, with EPS estimates ranging from $6.46 to $6.50. For the next year, analysts anticipate that the firm will report earnings of $7.36 per share, with EPS estimates ranging from $7.14 to $7.55. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.02. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The business had revenue of $604.57 million during the quarter, compared to analyst estimates of $587.65 million. During the same quarter in the previous year, the firm posted $1.29 EPS. The business’s revenue for the quarter was up 22.4% compared to the same quarter last year.

A number of research firms recently issued reports on CRL. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Svb Leerink began coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating and a $155.00 price target for the company. Evercore ISI reiterated an “outperform” rating and set a $160.00 price target on shares of Charles River Laboratories Intl. in a research report on Tuesday, April 30th. Barclays boosted their price target on Charles River Laboratories Intl. from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, March 18th. Finally, Wolfe Research began coverage on Charles River Laboratories Intl. in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $146.27.

NYSE:CRL traded down $1.07 during midday trading on Wednesday, reaching $138.37. 2,924 shares of the company traded hands, compared to its average volume of 385,872. Charles River Laboratories Intl. has a twelve month low of $103.00 and a twelve month high of $149.07. The stock has a market capitalization of $6.94 billion, a price-to-earnings ratio of 23.12, a price-to-earnings-growth ratio of 1.83 and a beta of 1.10. The company has a quick ratio of 1.39, a current ratio of 1.63 and a debt-to-equity ratio of 1.10. The firm has a fifty day moving average of $133.51.

In other news, insider William D. Barbo sold 4,905 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total value of $613,909.80. Following the completion of the sale, the insider now owns 25,859 shares in the company, valued at $3,236,512.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George Massaro sold 3,140 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $134.64, for a total value of $422,769.60. Following the completion of the sale, the director now owns 15,344 shares of the company’s stock, valued at approximately $2,065,916.16. The disclosure for this sale can be found here. Insiders have sold a total of 9,047 shares of company stock valued at $1,168,322 in the last quarter. 1.80% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in the company. Fort L.P. acquired a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth $27,000. Tompkins Financial Corp raised its position in shares of Charles River Laboratories Intl. by 63.1% during the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after purchasing an additional 77 shares during the period. Riverview Trust Co acquired a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth $30,000. Sageworth Trust Co acquired a new stake in shares of Charles River Laboratories Intl. during the first quarter worth $37,000. Finally, Kwmg LLC raised its position in shares of Charles River Laboratories Intl. by 32.4% during the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 94.37% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.